UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 22, 2008 (August 22, 2008)

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Tennessee		001-15875		54-1684963
(State or Other Jurisdiction		(Commission		(I.R.S. Employer
of Incorporation)		File Number)		Identification No.)

501 Fifth Street,		37620
Bristol, Tennessee		(Zip Code)
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (423) 989-8000

N/A

Former name or former address if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

x		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01.		Other Events.

     On August 22, 2008, King Pharmaceuticals, Inc. (“King”) issued a press release announcing its proposal to acquire all of the outstanding shares of common stock of Alpharma Inc. (“Alpharma”). The proposal was communicated on August 22, 2008 in a letter to the Board of Directors of Alpharma. The press release announcing the proposal, including the full text of the proposal letter delivered to the Board of Directors of Alpharma, is attached as Exhibit 99.1 to this Current Report and is incorporated herein by this reference.

Item 9.01.		Financial Statements and Exhibits.

     (d) Exhibits

	99.1			King Pharmaceuticals, Inc. Press Release, dated August 22, 2008.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 22, 2008

EXHIBIT INDEX

Exhibit No.				Description
	99.1			King Pharmaceuticals, Inc. Press Release, dated August 22, 2008.